Budget 2018 Reaction: Patients waiting for new medicines need a multi-annual solution

The Irish Pharmaceutical Healthcare Association has welcomed the reduction of prescription charges and the lowering of the Drugs Payment Scheme threshold in today.

Read more

Innovative medicines are a significant factor in contributing to advances in cancer care - IPHA

Responding to the publication of a study in the British Medical Journal (BMJ) concerning the benefits on overall survival and quality of life of approved cancer medicines, the IPHA, which represents 44 research based pharmaceutical companies in Ireland, many of whom are providing key oncology medicines, has stated that new therapies have contributed to significant declines in cancer death rates around the world since its peak in 1991.

Read more

IPHA launches report and infographic on how Ireland is falling behind in access to new medicines

IPHA has launched a briefing document which sets out how Irish patients are being denied access to new medicines that are readily available in other Western European countries. s.

Read more

IPHA Submission to National Biosimilar Medicines Consultation

In a submission made to the National Biosimilar Medicines Policy consultation process, the Irish Pharmaceutical Healthcare Association (IPHA) highlighted the importance of adopting a patient-centric policy on prescribing biologic and biosimilar medicines.  

Read more

IPHA welcomes confirmation delayed medicines will be made available for patients

The Irish Pharmaceutical Healthcare Association welcomes the statement by the HSE confirming that it will fund nine delayed medicines for prescribing to patients. 

Read more

Crunch meeting fails to clear new medicines logjam

Thousands of patients in Ireland, with serious conditions ranging from heart disease, cancer and skin condition are being denied access to nine new medicines that are routinely available across Europe.

Read more

Timely reimbursement of innovative medicines important for new National Cancer Strategy

The Irish Pharmaceutical Healthcare Association (IPHA) has welcomed the new National Cancer Strategy and highlighted the fact that a timely reimbursement system must be in place if it is to deliver on its objectives.

Read more